Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

SCYNEXIS Inc

SCYX ✗ NOT COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$4.84

▲ +2.98%

Market Cap $48.16M · Vol 9.61K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$48.16M

Micro Cap

Div Yield

N/A

EPS Growth

-109.56%

YoY

RSI (14)

44.01

Momentum

Beta

1.06

vs Market

52W High

$10.40

53.46% below

52W Low

$3.54

36.72% above

Volume

9.61K

Avg 41.09K

P/B

0.56

Price-to-book

ROE

N/A

Return on equity

Free Float

98.00%

Public shares

Shariah Compliance8 STANDARDS

✗ SCYNEXIS Inc (SCYX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SCYX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-9.45%

+0.10%

+14.02%

-32.17%

YTD

-4.33%

-48.73%

-82.76%

-91.04%

Financials & Valuation

TTM · Annual

Total Revenue	$20.60M
Net Income	$-8,609,000.00
Revenue Growth (YoY)	-82.77%
Gross Margin	100.00%
Operating Margin	-78.03%
Net Profit Margin	-41.79%
ROE	N/A
ROA · ROIC	-11.50% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.53
P/B	0.56
P/FCF	N/A
EPS Growth	-109.56%
Outstanding Shares	9.95M

Technical Indicators

50-Day SMA	$4.79
200-Day SMA	$5.69
RSI (14)	44.01
Beta	1.06
52-Week High	$10.40
52-Week Low	$3.54

Volume Today	9.61K
Avg Daily Volume (30D)	41.09K
Relative Volume	0.23x
Volatility (10D)	40.25
Volatility (30D)	91.91
Free Float	98.00%

Analyst Consensus

BUY

Current Price $4.84

Mean Target $36.55

52W Low$3.54 52W High$10.40

Current

Target

$3.54 $10.40

Current Analyst target

+655.17% upside potential · 3 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG002133YY2

ISINUS8112923094

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company -0.65% JNJ Johnson & Johnson -0.29% ABBV AbbVie Inc. +0.83% NVS Novartis AG -0.23% NOVN.S Novartis AG -0.09%

Company Profile

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).